SCHEMBL6177973

SCHEMBL6177973

CC(=O)OCCc1c(N)cc(N(C=O)OCc2ccccc2)c2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.43
ALDH1A1 P00352 3/20 0.39
TSHR P16473 2/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
GLA P06280 2/20 0.34
HPGD P15428 2/20 0.34
MAPK1 P28482 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
TP53 P04637 1/20 0.34
CYP3A4 P08684 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HIF1A Q16665 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ALOX5 P09917 3/20 0.33
AKR1B10 O60218 4/20 0.33
AKR1B1 P15121 4/20 0.33
HCAR2 Q8TDS4 2/20 0.33
AKR1C4 P17516 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5732923 0.83 RAD52 (0.45) RAD52
SCHEMBL5736091 0.77 RAD52 (0.46) RAD52ALDH1A1TSHRNPC1RAB9A
SCHEMBL5736235 0.75 ALDH1A1 (0.38) RAD52ALDH1A1HPGDTP53ALOX5
SCHEMBL5732905 0.75 KDM4E (0.48) ALDH1A1TSHRNPC1RAB9ACYP3A4
SCHEMBL6177969 0.74 NPC1 (0.48) RAD52ALDH1A1TSHRNPC1RAB9A
SCHEMBL5733771 0.69 MEN1 (0.36) ALDH1A1NPC1RAB9AHPGDMAPK1
SCHEMBL5737111 0.69 MEN1 (0.39) ALDH1A1NPC1RAB9AMAPK1TDP1
SCHEMBL5736112 0.69 HSP90AA1 (0.36) ALDH1A1NPC1RAB9AMAPK1CYP3A4
SCHEMBL5733910 0.69 MEN1 (0.37) ALDH1A1NPC1RAB9AMAPK1CYP3A4
SCHEMBL5735296 0.68 RAD52 (0.42) RAD52ALDH1A1NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1320522-B1 COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS TAIHO PHARMACEUTICAL CO LTD (JP) 2005-11-23 EP disclosed
US-6660742-B2 Alkylation therapy; anticancer agent TAIHO PHARMACEUTICAL CO. LTD. (JP) 2003-12-09 US disclosed
US-20030073731-A1 Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins MEDIMMUNE LIMITED (GB) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073731-A1 Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins DDB1, ERCC2, SSU72 RAD52 50/4885ALDH1A1 3356/4885TSHR 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.